Showing 2431-2440 of 3039 results for "".
- Viatris Closes Acquisitions of Oyster Point Pharma and Famy Life Sciences, Establishing New Eye Care Divisionhttps://modernod.com/news/viatris-closes-acquisitions-of-oyster-point-pharma-and-famy-life-sciences-establishing-new-viatris-eye-care-division-1/2481326/Viatris announced that it has closed its acquisitions of Oyster Point Pharma and Famy Life Sciences to establish a new Viatris Eye Care Division. The transaction was first announced on November 7. Former Oyster Point Pharma CEO, Jeffrey Nau, PhD, MMS, will lead the new di
- EyePoint Pharmaceuticals Promotes Jay S. Duker, MD, to President and Chief Operating Officerhttps://modernod.com/news/eyepoint-pharmaceuticals-promotes-jay-s-duker-md-to-president-and-chief-operating-officer/2481320/EyePoint Pharmaceuticals announced that Jay S. Duker, MD, who has served as the company’s Chief Operating Officer (COO) since November 2021, has been promoted to the additional role of President. In addition to continuing to oversee his duties as COO, in his expanded role, Dr. Duker wi
- Elios Vision Announces Registration of Elios in the United Kingdomhttps://modernod.com/news/elios-vision-announces-registration-of-elios-in-the-united-kingdom/2481318/Elios, a technology used to treat glaucoma at the same time as cataract surgery, is now registered for use in the United Kingdom, according to Elios Vision. The Elios does not require an implant and is designed to provide long-lasting results that may free patients and th
- Outlook Therapeutics Closes $55 Million Financing; Extends Cash Runway Through Anticipated FDA Approval of ONS-5010https://modernod.com/news/outlook-therapeutics-closes-55-million-financing-extends-cash-runway-through-anticipated-fda-approval-of-ons-5010/2481313/Outlook Therapeutics announced it closed on approximately $25 million registered direct equity offering, and about $30 million net proceeds from issuance of an unsecured convertible promissory note with an initial conversion price of $2. The $50 million net proc
- Opus Genetics Acquires Rights to Two Gene Therapy Product Candidates for Inherited Retinal Diseases from Iveric Biohttps://modernod.com/news/opus-genetics-acquires-rights-to-two-gene-therapy-product-candidates-for-inherited-retinal-diseases/2481311/Opus Genetics announced it has acquired the rights to two preclinical-stage AAV-based gene therapy product candidates for inherited retinal diseases (IRDs) from Iveric Bio. Opus will develop the novel gene therapy candidates to address bestrophin-1(BEST1)-related inherited retinal diseases a
- Iveric Bio Completes Rolling NDA Submission to FDA for Avacincaptad Pegol for the Treatment of Geographic Atrophyhttps://modernod.com/news/iveric-bio-announces-completion-of-rolling-nda-submission-to-fda-for-avacincaptad-pegol-for-the-treatment-of-geographic-atrophy/2481305/Iveric Bio announced that it has submitted to the FDA the third and final part of its new drug application (NDA) for rolling review of avacincaptad pegol (ACP), a novel investigational complement C5 inhibitor for the treatment of geographic atrophy (GA) secondary to age-related macular degen
- Elios Vision Announces Registration of Elios in Francehttps://modernod.com/news/elios-vision-announces-registration-of-elios-in-france/2481304/Elios Vision announced that its Elios technology, which is used to treat glaucoma at the same time as cataract surgery, is now registered in France. Elios does not require an implant and is designed to provide long-lasting results that may free patients from drop therapy.
- Oxurion Announces the Continuation of KALAHARI Phase 2, Part B Study in DME Following Interim Analysishttps://modernod.com/news/oxurion-announces-the-continuation-of-kalahari-phase-2-part-b-study-in-dme-following-interim-analysis/2481293/Oxurion NV announced that an Independent Data Monitoring Committee (IDMC) completed its planned interim analysis of the KALAHARI phase 2, Part B clinical trial evaluating Oxurion’s novel plasma kallikrein (PKal) candidate, THR
- Eversight and the Department of Health–Abu Dhabi Partner to Establish UAE’s First Eye and Tissue Bankhttps://modernod.com/news/eversight-and-the-department-of-health-abu-dhabi-partner-to-establish-uaes-first-eye-and-tissue-bank/2481291/Global nonprofit eye bank Eversight and the Department of Health – Abu Dhabi (DoH) are partnering to establish the first eye and tissue bank in the United Arab Emirates (UAE). The
- Visiox Pharma Announces FDA Acceptance of NDA for Glaucoma Drug Candidatehttps://modernod.com/news/visiox-pharma-announces-fda-acceptance-of-nda-for-glaucoma/2481285/Visiox Pharma announced that it has received notification from the FDA that the agency has completed its filing review and accepted for filing the new drug application (NDA) for PDP-716 (0.35% brimonidine tartrate) for the treatment of glaucoma. The FDA has assigned a Prescrip